MPC 1203

Drug Profile

MPC 1203

Latest Information Update: 09 Aug 2007

Price : $50

At a glance

  • Originator Myriad Pharmaceuticals; Nonindustrial source
  • Class
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Disseminated intravascular coagulation; Thrombosis

Most Recent Events

  • 09 Aug 2007 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
  • 09 Aug 2007 Discontinued - Preclinical for Disseminated intravascular coagulation in USA (unspecified route)
  • 09 May 2001 Preclinical development for Thrombosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top